Author:
Boucau Julie,Uddin Rockib,Marino Caitlin,Regan James,Flynn James P.,Choudhary Manish C.,Chen Geoffrey,Stuckwisch Ashley M.,Mathews Josh,Liew May Y.,Singh Arshdeep,Reynolds Zahra,Iyer Surabhi L.,Chamberlin Grace C.,Vyas Tammy D.,Vyas Jatin M.,Turbett Sarah E.,Li Jonathan Z.,Lemieux Jacob E.,Barczak Amy K.,Siedner Mark J.
Abstract
AbstractWe enrolled seven individuals with recurrent symptoms following nirmatrelvir-ritonavir treatment. High viral loads (median 6.1 log10 copies/mL) were detected at enrollment and for a median of 17 days after initial diagnosis. Three of seven had culturable virus for up to 16 days after initial diagnosis. No known resistance-associated mutations were identified.
Publisher
Cold Spring Harbor Laboratory
Reference8 articles.
1. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19;N Engl J Med,2022
2. Therapeutic Management of Nonhospitalized Adults With COVID-19. Available at: https://www.covid19treatmentguidelines.nih.gov/management/clinical-management/nonhospitalized-adults--therapeutic-management/. Accessed 20 May 2022.
3. Charness M , Gupta K , Stack G , et al. Rapid Relapse of Symptomatic Omicron SARS-CoV-2 Infection Following Early Suppression with Nirmatrelvir/Ritonavir. 2022. Available at: https://www.researchsquare.com. Accessed 20 May 2022.
4. Siedner MJ , Boucau J , Gilbert RF , et al. Duration of viral shedding and culture positivity with post-vaccination SARS-CoV-2 delta variant infections. JCI Insight 2021; :e155483.
5. Seaman MS , Siedner MJ , Boucau J , et al. Vaccine Breakthrough Infection with the SARS-CoV-2 Delta or Omicron (BA.1) Variant Leads to Distinct Profiles of Neutralizing Antibody Responses. medRxiv 2022; :2022.03.02.22271731.